Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 205Carcinoma, Non-Small-Cell Lung 130Neoplasms 101Neoplasm Metastasis 70Breast Neoplasms 66Ovarian Neoplasms 42Urinary Bladder Neoplasms 37Lung Neoplasms 37Triple Negative Breast Neoplasms 34Colorectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Cholangiocarcinoma 28Biliary Tract Neoplasms 27Carcinoma, Transitional Cell 23Lymphoma, Non-Hodgkin 22Adenocarcinoma 22Recurrence 21Lymphoma 20Fallopian Tube Neoplasms 18Stomach Neoplasms 15Sarcoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 15Non-Muscle Invasive Bladder Neoplasms 13Carcinoma, Pancreatic Ductal 13Nasopharyngeal Carcinoma 12Gallbladder Neoplasms 12Bile Duct Neoplasms 11Melanoma 10Carcinoma 10Solid Tumors 9

Interventions

Gemcitabine 1Albumin-Bound Paclitaxel 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cholestasis × Gemcitabine × Clear all
NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Celgene

Phase 1 Terminated
1 enrolled
Gastrointestinal

Cholestasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡